Navigation Links
Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share
Date:11/10/2009

$119 (82%) $17 $385 (96%) Operating Margin Before Special Items 6.4% 20.1% 1.2% 16.9%

Revenue of $326 million declined 45% in the quarter with an organic revenue decline of 41%. The decline was primarily due to lower selling prices for both steel and copper products.

Operating income was $12 million in the quarter and included $9 million of special items for restructuring activities. Operating income before special items of $21 million decreased $98 million, primarily due to lower spreads for both steel and copper products. The operating margin before special items was 6.4%.

Full year revenue of $1.4 billion decreased 39% with an organic revenue decline of 35%. Electrical and Metal Products incurred an operating loss of $940 million which included special items of $957 million. Operating income excluding special items was $17 million.

Safety Products


                           Q4 2009  Q4 2008 % Change FY 2009 FY 2008 % Change
                           -------  ------- -------- ------- ------- --------
    Revenue                   $382     $507     (25%)  $1,552  $1,934  (20%)
     Operating Income          $46      $65     (29%)   ($789)   $284     -
     Operating Margin         12.0%    12.8%                -    14.7%
     Special Items            ($14)    ($34)          ($1,018)   ($73)
     Operating Income Before
      Special Items            $60      $99     (39%)    $229    $357  (36%)
     Operating Margin Before
      Special Items           15.7%    19.5%             14.8%   18.5%

Revenue of $382 million declined 25% in the quarter. Organic revenue declined 22% due to lower volume across the Fire Suppression, Electronic Security and Life Safety businesses resulting from weaker demand in end markets.

Operating income was $46 million in the quarter and the operating margin was 12.0%. Special items of $14
'/>"/>

SOURCE Tyco International Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research
2. Tyco International to Present at the Citi Industrial Manufacturing & Transportation Conference
3. AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation
4. HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China
5. Allied Worlds Nicole Baummer and Marjorie Thompson to Speak at PLUS International Conference
6. Service Corporation International Announces Third Quarter 2009 Financial Results
7. Stenum Hospital Kicks off International Rollout of M6 Artificial Lumbar Disc Replacement Surgery
8. FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDAs international posts, LASIK eye surgery, and FDA MedWatch safety alerts
9. Service Corporation International Announces Schedule for Its Third Quarter 2009 Earnings Release and Conference Call
10. Blue Cross and Blue Shield of Floridas Power of the Human Voice Campaign Wins Prestigious DMA International ECHO Gold Award
11. MediSend International Joins the Clinton Global Initiative With the Afghanistan Health and Human Resource Initiative

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...od pressure readings in children with chronic kidn... during doctor,s office visits increasing a child...esearch from Johns Hopkins Children,s Center and o...s online in the Journal of American Society of Nep... measurements obtained during regular doctor visit...
(Date:11/20/2009)...nks it,s as short as 34 weeks, potentially adding ..., FRIDAY, Nov. 20 (HealthDay News) -- Recent repor...ues to climb in the United States. Now, a new stu...d about what constitutes a full-term birth in the ... surveyed in the study considered a baby born at 3...
(Date:11/20/2009)...ctivity remains high and is expected to continue, ...y News) -- Some areas of the United States are see... health official said Friday, and while the diseas...m the 46 states reported last week. , "We are b...y around the country, but there is still a lot of ...
(Date:11/20/2009)... SPRINGFIELD, Mo., Nov. 20 Missour...al Missouri regions will now have the option to ch...ched Tuesday between Missouri Consolidated Health ...e Southwest and South Central Missouri regions inc... Christian, Dade, Dallas, Douglas, Greene, Hickory...
(Date:11/20/2009)... BATON ROUGE, La., Nov. 20 /PRNewswire-USNewswir...(LAHP) today warned that Louisianians could experi...its if proposals being considered by Congress shou... executive officer for LAHP, "Louisiana health pla... since the beginning of the national debate. Our ...
Breaking Medicine News(10 mins):Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2
...7 Merck & Co., Inc.,today said that it has not ye...k State and New York City seeking Medicaid reimbur...t the suit as it has defended against the,Medicaid...ug Administration (FDA) approval, and consistently...
...or Living,Inc. (NYSE: BKD ) announced today that ...sh dividend on its common stock of $0.50 per share....50 per share dividend is payable,on October 12, 2...ving facilities throughout the United States. The ...
...Biosciences,Inc. (LSE: AKR) which develops, manufa...g and testing products, is pleased to announce tha...Army for the purchase of its,BreathScan alcohol sa...gnificant,orders from several departments of the U...
... Focus on Cardiovascular Disease, Prevention and ...e Care Improvements, ...Charlie,Rose Science Series" on PBS will focus on ...l Laureate and President of,Rockefeller University...
...hat patients with cancer in the head and neck regi...kills compared with individuals without the diseas... Archives of Otolaryngology-Head & Neck Surgery, o...ork together. These functions can be compromised t...
...rday, October 20,Event to be held in honor of Octo...PLAINS, Mo., Sept. 17 GAMMILL QUILTING SYSTEMS, a...ngarm quilting systems, in,cooperation with it,s n...tional Breast Cancer Awareness Month; and in,suppo...
Other Medicine News:Health News:Merck & Co., Inc. Response to Today's New York Medicaid Suit 2Health News:Merck & Co., Inc. Response to Today's New York Medicaid Suit 3Health News:Akers Biosciences, Inc. 'ABI' or the 'Company' Receipt of Further United States Military Contracts 2Health News:Charlie Rose Science Series Explores Heart Disease 2Health News:Charlie Rose Science Series Explores Heart Disease 3Health News:Patients with head and neck cancer may have impairment of some driving skills 2Health News:'Think Pink with Gammill(R)' 2
(Date:11/20/2009)...Newswire-FirstCall/ -- Smith & Nephew ( SNN, L...ce the signing of a technology development contrac...t may lead to the creation of a fracture fixation ...the limbs of soldiers who sustain battlefield inju...ch Projects Agency (DARPA), the central research a...
(Date:11/19/2009)... BioCryst Pharmaceuticals...g of a public offering of 5,000,000 shares of its ...s proceeds of $48.75 million. All of the shares a...ive shelf registration statement previously filed ...ryst has also granted the underwriters a 30-day op...
(Date:11/19/2009)...9 /PRNewswire-Asia/ -- ScinoPharm, a leading globa...PIs), announced that its,Tainan facility has recei...SafeBridge(R) Consultants, Inc. The Certification ...n the safe handling of potent active,pharmaceutica...ratories and,production areas used for the manufac...
Breaking Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2CQ Forum on Biosimilar Biological Products Wed June 17 2009 12618 1Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 1Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 2Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 3Coming Soon 3A Lung Cancer Spray 3F 48863 1Coming Soon 3A Lung Cancer Spray 3F 48863 2
...in Long-term PASI 75, Response and Marked Improve... Study Findings, BUENOS AI...s from an international, Phase 3 study showed that... severe plaque psoriasis receiving,two doses of us...nt,reduction in psoriasis at week 12, the primary ...
...es, Inc. (Nasdaq: RMTI ), a leading, innovative m...ialty pharmaceuticals focused on the end-,stage-re... has begun dosing,patients in its Phase IIb Dose-R...hate (SFP), the Company,s physiological iron-maint...n is a double-blind, multi-center,randomized, plac...
Other Medicine Technology:Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 2Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 3Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 4Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 5Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 6Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 2Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 3Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 4
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: